Neurocrine biosciences presents ingrezza® (valbenazine) data on sustained treatment response at psych congress 2022

San diego , sept. 19, 2022  /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present data demonstrating sustained improvements with long-term ingrezza® (valbenazine) capsules treatment in adults with tardive dyskinesia (td) at the psych congress 2022 scientific meeting being held september 17-20.
NBIX Ratings Summary
NBIX Quant Ranking